Nasacort OTC Dual Allergy/Decongestion Relief Could Be Marketing Edge

Sanofi’s Nasacort likely can carve out sales in the crowded nonprescription allergy market with promises of allergy relief plus decongestion in a product available OTC, unlike most competitors including Claritin D, Zyrtec D and Allegra D, which contain pseudoephedrine and are sold behind-the-counter.

Sanofi’s Rx-to-OTC switch Nasacort Allergy 24HR will be positioned in the crowded allergy category as providing dual relief from allergy and decongestion as an OTC, while most competitors offering both are sold behind the counter.

While its dual role and OTC status might provide a marketing edge, the brand still must overcome potential barriers that could hamper sales, such as consumer preference for pills over sprays, weaker brand

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

More from North America